{"organizations": [], "uuid": "742dffe04f686cd3e2a1d22d2f086e103ccf8bc6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/walgreens-boots-results/walgreens-reports-12-percent-rise-in-sales-idUSL3N1RA4J7", "country": "US", "domain_rank": 408, "title": "Walgreens reports 12 percent rise in sales", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T14:09:00.000+03:00", "replies_count": 0, "uuid": "742dffe04f686cd3e2a1d22d2f086e103ccf8bc6"}, "author": "", "url": "https://www.reuters.com/article/walgreens-boots-results/walgreens-reports-12-percent-rise-in-sales-idUSL3N1RA4J7", "ord_in_thread": 0, "title": "Walgreens reports 12 percent rise in sales", "locations": [], "entities": {"persons": [{"name": "uday sampath", "sentiment": "none"}, {"name": "tamara mathias", "sentiment": "none"}, {"name": "saumyadeb chakrabarty", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "negative"}, {"name": "walgreens", "sentiment": "negative"}, {"name": "am / updated", "sentiment": "negative"}, {"name": "walgreens boots alliance inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 10 AM / Updated 3 minutes ago Walgreens reports 12 percent rise in sales Reuters Staff 1 Min Read \nMarch 28 (Reuters) - Walgreens Boots Alliance Inc reported a 12 percent increase in quarterly sales on Wednesday as the drugstore chain filled more prescriptions, helped by its partnership with pharmacy benefit manager Prime Therapeutics. \nNet income attributable to the company rose to $1.35 billion, or $1.36 per share, in the second quarter ended Feb. 28, from $1.06 billion, or 98 cents per share, a year earlier. \nNet sales rose to $33.02 billion from $29.45 billion. (Reporting by Uday Sampath and Tamara Mathias in Bengaluru Editing by Saumyadeb Chakrabarty)", "external_links": [], "published": "2018-03-28T14:09:00.000+03:00", "crawled": "2018-03-28T14:16:38.001+03:00", "highlightTitle": ""}